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1. INTRODUCTION 
An ideal dosage regimen in the drug therapy of any disease is the one, which 
immediately attains the desire therapeutic concentration of drug in plasma (or at the 
site of action) and maintains it constant for the entire duration of treatment. The drug 
may be administered by variety of routes in a variety of dosage forms. Drugs are more 
frequently taken by oral administration. The solid dosage forms available mostly in 
unit dosage forms such as tablets, capsules, lozenges etc¹. When drugs are 
administered orally in dry state, tablets and capsules are most convenient dosage 
form².All practical purposes only compression tablets are almost universally used 
while molded tablets being rate commodity. Drugs are more frequently taken by oral 
administration³. 
Although a few drugs taken orally are intended to be dissolved within the 
mouth, vast majority of drugs taken oral are swallowed4. Compared with alternate 
routes, the oral route of drug administration is the most popular and has been 
successfully used for the conventional delivery of drug5. 
It is considered most natural, uncomplicated, convenient, safe means of 
administering drugs6. Some of its advantages are greater flexibility in dosage design, 
ease of production and low cost7. 
Many patients find it difficult to swallow tablets and hard gelatin capsules and 
thus do not comply with prescription, which results in high incidence of non-
compliance and ineffective therapy. Recent advances in novel drug delivery systems 
(NDDS) aim to enhance the safety and efficacy of drug molecule by formulating a 
convent dosage form for administration and to achieve better patient compliance8. 
Nearly 35 - 50% of the general population, especially the elderly and children 
suffer from dysphasia or difficulty in swallowing, which results in high incidence of 
non-compliance and ineffective therapy9. Swallowing problems also are very common 
in young individuals because of their poorly developed muscular and nervous 
systems. Other groups who may experience problems in swallowing conventional oral 
dosage forms are the patients with tremors of extremities, mentally ill, develop 
mentally  disabled, non-cooperative and patients with reduced liquid intake or patients 
suffering from nausea, as well as patients travelling or who do  not have easy access 
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to water. The swallowing problems are also common in some cases such as patients 
with motion sickness, sudden episodes of allergic attack or coughing and due to lack 
of water. 
To overcome this problem, scientists have developed innovative drug delivery 
system known as a ''Immediate release tablets10”. 
Immediate release tablets are designed to disintegrate and release their 
medication in absence of any special rate-controlling features as special coating and 
others techniques11. 
1.1Advantages of Immediate Release Tablets12,13,14; 
1. Large scale manufacturing is feasible in comparison to other dosage forms, 
therefore economy can be achieved. 
2. Accuracy of dosage is maintained since tablet is a solid unit dosage form. 
3. Longer expiry period and microbial spillage owing to lower moisture content. 
4. Easy of packaging (blister or strip)and easy handling over liquid a form. 
5. Easy to transport in bulk. Emergency supplies can be carried by patients. 
6. Easy to transport in bulk. Emergency supplies can be carried by patients15. 
7. Product identification is easy and marking done with the help of grooved punched 
and printing with edible ink, 
 Disadvantages of Immediate Release Tablets16,17; 
1. It is difficult to convert a high dose poorly compressible API into tablet of 
multiple size for human use18. 
2. Difficult to formulate a drug with poor wet ability, slow dissolution in to tablet. 
3. Slow onsets of action as compared to parenterals, liquid orals are capsules. 
4. Difficult to swallow for kids, terminally ill and geriatric patients. 
5. Patients undergoing radiotherapy cannot swallow tablet. 
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1.2. Desired Criteria For Immediate Release Drug Delivery System (IRDS): 
Immediate release dissolving tablet should address the following: 
 Requires no water for oral administration, but it should dissolve or disintegrate in 
the mouth in matter of seconds. 
 Be compatible with taste masking agent. 
 Be portable. 
 Have a pleasing mouth feel. 
 Leave minimal or no residue in the mouth after oral administration. 
 Exhibit low sensitivity to environmental condition as humidity and temperature. 
 Allow high drug loading. 
 Allow the manufacturing of tablets using conventional processing and packaging 
equipments at low cost.                                   
1.2.1. Salient Features of Immediate Release Drug Delivery System: 
Ease of administration to patient who refuses to swallow a tablet, such as pediatric, 
geriatric and psychiatric patients. 
 Require no water to swallow the dosage form, which is highly convenient feature 
for patients who are travelling and do not have immediate access to water. 
 Rapid dissolution and absorption of drug, which will produce quick onset of 
action. 
 Some drugs are absorbed from the mouth, pharynx and esophagus as the saliva 
passes down into the stomach; in such cases bioavailability of drug is increased. 
 Pregastric absorption can result in improved bioavailability and as a result of 
reduced dosage; improve clinical performance through a reduction of unwanted 
effects. 
 Direct compression is the easiest method to manufacture immediate release 
tablets (IRTs) and immediate melting tablets (IMTs). The great advantages of direct 
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compression are its low manufacturing cost. It uses conventional equipment, 
commonly available excipients and a limited number of processing steps. 
 Direct compression is the method of choice in tablet manufacture to produce 
high quality finished product and applied to prepare dispersible tablets18. 
 In direct compression method, previously only crystalline compounds or 
materials were considered to be directly compressed, but now the scenarios changing 
and this technique is being applied for many non -crystalline materials too. 
Formulations constituted by <-25% w/w of drug material are easy to be directly 
compressed by simply using diluents, which are easy to be compressed and which acts 
as a carrier for the drug19. 
1.2.2. FACTORS AFFECTING THE DRUG RELEASE20:  
1. Physiochemical properties of drug and  
2. Dosage form factors 
The various physiochemical properties of drug that effect drug dissolution and 
its rate are - solubility, partical size, polymorphism, salt form, pseudo-polymorphism, 
complexation, wetability etc. 
Dosage form factors include manufacturing process and excipients 
incorporated in them21. 
Several manufacturing process influence drug dissolution form. Processes of 
such importance in manufacturing of tablets are; 
1. Method of granulation 
2. Compression force. 
The excipients such as binders, lubricants, disintegrants, etc influence the drug 
dissolution26. 
The techniques used in the preparation of immediate release tablets: 
1.3.Conventional Techniques22,23,24; 
1. Tablet moulding: 
 In this method, the delivery system is prepared in the form of tablets using 
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water soluble additives to allow the tablet to dissolve rapidly and completely in 
mouth. All the ingredients of the formulation are passed through fine mesh dry 
bended, wetted with a hydro - alcoholic solvent and then compressed into tablets 
using low compression forces. The solvent is then removed by air drying. 
2. Freezing drying: 
Lyophilisation is a pharmaceutical manufacturing technology, which allows 
drying of heat sensitive drugs and biological at low temperature under conditions that 
allow removal of water by sublimation. Lyophilization results in preparations which 
are highly porous, with a very high specific surface area, which dissolve rapidly a 
show improved absorption and bioavailability. 
3. Spray drying: 
 Spray drying is a process by which highly porous, fine powders can be 
produced. The composition contains a bulking agent (mannitol and lactose), a 
disintegrate (sodium starch glycol ate and caramelize sodium), an acidic ingredient 
(citric acid) and / or alkaline ingredients (sodium bicarbonate) which when 
compressed into tablets show fast disintegration and enhanced dissolution. 
4. Sublimation: 
 This method includes the addition of a sublime of a sublime salt to the table 
ting components, compressing the blend and removing the salt by the process of 
sublimation. The active ingredient, diluents, a sublime salt (camphor / ammonium 
bicarbonate) a binder and other excipient are blended and tablets are prepared. 
5. Addition of disingredients: 
 Addition of disingredients in immediate release tablets, leads to quick 
disintegration of tablets and hence improves dissolution. Microcyrstalline cellulose, 
cross-linked carboxy methyl cellulose sodium, cross-linked polyvinyl pyrolidine and 
partially substituted hydroxy propel cellulose, absorb water and swell due to capillary 
action and are considered as effective disintegrates in the preparation of immediate 
releasing tablets. 
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6. Sugar based excipient: 
 Sorbitol, mannitol, dextrose, xylitol, fructose, maltose and polydextrose have 
been used as abulking agents. Because of their high aqueous solubility and sweetness, 
which impart a pleasing mouth feel and good taste masking, nearly all formulations 
for rapidly dissolving tablets contain sugar based materials. 
7. Mass Extrusion: 
 This technology involves softening the active blend using the solvent, mixture 
of water soluble polyethylene glycol using methanol and explusion of softened mass 
through the extruder or syringe to get a cylinder of the product and cutting into even 
segments upon heated blade to form tablets. 
Patented Technologies: 
8. Zydis: 
 In zydistechnology, drug is added to a solution carrier material (preferably 
gelatin) to obtain dispersion, and the dispersion is filled into performed pockets of 
blister pack by automatic means and freeze dried to produce the final dosage form. 
9. Orasolv: 
 The system essentially make tablets that contain the taste masked active 
ingredients an effervescent disintegrating agent, which on contact with saliva, rapidly 
disintegrates and releases the active ingredient. The tablets are made by direct 
compression at very low compression forces in order to minimize oral dissolution 
time. The tablets produced are soft and friable. 
10.Durasolv: 
 The tablet made by this technology consists of a drug, filler and a lubricant. 
Dura Solve tablets are prepared by using conventional tableting equipment and have 
good rigidity. 
11. Flash dose: 
 Flash dose tablets consist of self-binding shear form matrix termed as ''floss''. 
Shear form materials are prepared by flash heat processing and are of two types.  
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• Single floss  
• Dual floss 
1.4. SUPER DISINTEGRANTS 
 Disintegrates have a major in the disintegration and dissolution process of or 
dispersible tablets made by direct compression 25. The choice of a suitable type and 
optimal amount of disintegrant is important for ensuring high disintegration rate. The 
addition of other formulation components such as water soluble excipient or 
effervescent agents further enhance dissolution or disintegration properties26. The 
understanding of disintegrant properties and their effect on formulation has advanced 
significantly during last few years practically regarding superdisintegrants27. 
 Addition of super disintegrates in ODTs leads to quick disintegration of tablets 
and hence improves dissolution. Microcrystalline cellulose, crosslinked carboxy 
methyl cellulose sodium, crosslinked Polyvinyl pyrrolidone and partially substituted 
hydroxy propyl cellulose etc absorb water and swell due to capillary action and are 
considered as effective disintegrants in the preparation immediate release of tablets28. 
1.4.1. MECHANISM OF SUPERDISINTEGRANTS 
 The tablet breaks to primary particles by one or more of the mechanism listed 
below. 
1. Because of heat of wetting (air expansion): 
 When disintegrates with exothermic properties gets wetted, localized stress is 
generated due to capillary air expansion, which helps in disintegration of tablet. This 
explanation however, is limited to only a few types of disintegrates and cannot 
describe the action of most modern disintegrating agents. 
2. Swelling: 
           The most widely used mechanism of action for tablet disintegration is swelling. 
Tablets with high porosity show poor disintegration due to lack of adequate swelling 
force. swelling force is exerted in the tablet with low porosity. 
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3. Porosity and capillary action (Wicking): 
 The first step for this is disintegration by capillary action. The tablet will be 
put into the suitable aqueous medium; the medium penetrates into the tablet and 
replaces the air adsorbed on the particles. Which uptake by tablet depends upon 
hydrophilicity of the drug/ excipient and on tableting conditions. 
4. Due to disintegrating particle/particle repulsive forces: 
 Another mechanism of disintegration attempts to explain the swelling of tablet 
made with “non-swellable” disintegrates. Guyot – Hermann has proposed a particle 
repulsion theory based on the observation that non-swelling particle also cause 
disintegration of tablets.  
5. Due to deformation: 
 During tablet compression, disintegrated particles get deformed and those 
deformed particles get into their normal structure when they come in contact with 
aqueous media or water. The swelling capacity of starch was improved when granules 
were extensively deformed during compression. This increase in size of the deformed 
particles produce produces a breakup of the tablet. This type of mechanism of starch 
has been recently to be studied. 
6. Due to release of gases: 
 Carbon dioxide released within tablets on wetting due to interaction between 
bicarbonate with citric acid or tartaric acid. The tablet disintegrates due to generation 
of pressure within the tablet. 
Table No 1: List of Superdisintegrants 
Super disintegrants Examples Mechanism of action 
Croscarmellose® Cross Linked Cellulose Sweling and Wickling 
Crospovidone Cross linked PVP Very little swelling, act by 
capillary action.  
Sodium starch glycolate Cross linked starch Swelling 
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Alginic acid NF Cross linked Alginic acid Rapid swelling and wicking 
action 
Natural super disintegrants   
Calcium silicate(20 – 40%)  Wicking action 
 
1.5.Techniques for Solubility Enhancement 
 There are various techniques available to improve the solubility of poorly 
soluble drugs, some of the approaches to improve the solubility are: 
1. Physical Modification: 
A.Particle size reduction 
a. Micronization 
b. Nanosuspension 
B.Modification of the crystal habit 
a. polymorphs 
b. Pseudopolymorphs 
C. Drug dispersion in carriers 
a. Eutectic mixtures 
b. Solid dispersions 
c. Solid solutions 
D. Complexation 
a. Use of complexing agents 
E. Solubilization by surfactants: 
a. Microemulsions 
b. Self microemulsifying drug delivery systems 
2. Chemical Modifications 
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1.6. Solid dispersion Technique29: 
 40 - 60% of drugs used in pharmaceutical industry are poorly water soluble or 
lipophilic compounds. Poorly water soluble drugs show unpredictable absorption, 
since their bioavailability depends upon dissolution in the GIT. The dissolution 
characters of poorly water soluble drugs can be enhanced by several methods like pH 
adjustment, salt formation, co-crystallization, co-grinding, cosolvency, hydrotrophy, 
solubilization, size reduction like micronization, nano technology, complexation, and 
drug dispersion in carriers30. The solid dispersion can be prepared by fusion 
method,melting method, solvent method, Hot meltbextrusion method and 
Supercritical fluid method. 
a. Fusion Method: 
 The fusion method is sometime otherwise called as melting method, if the 
starting material is crystalline. In this method, the carrier is heated to a temperature 
just above its melting point and the drug is incorporated in to the matrix. The first 
dispersion of sulfathiazole and urea was prepared by fusion method, by melting at the 
eutectic composition followed by cooling step. Polymers like Polyethylene glycols 
and Poly (vinyl pyrolidone) PVP are mostly used in this method. 
Limitations: 
• This method is suitable if the drug and polymer are compatiable and can be mixed 
homogeneously at the heating temperature in order to prevent formation of two 
incompatible liquids phases or a suspension in heated mixture. This problem can 
be overcome by using surfactants. 
• Sometimes this problem during cooling stage when the drug – matrix miscibility 
changes which may produce phase separation. This problem is observed when 
cooling is done at slow rate, resulting in formation of crystalline drug.  
• This method is not suitable if the carrier is high – melting solid and the drug is 
heat sensitive. 
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b. Hot melt extrusion method: 
 This method is same as fusion method except that the intensive mixing is 
included by the extruder. In this method twin – screw extruder or single extruder is 
used. This method offers the potential to shape the heated mixture in to implants, 
implants inserts, oral dosage forms. To detect the solid – state solubility and to select 
matrix suitable for melt extrusion, the solubility parameters are investigated. Higher 
shear forces resulting in high temperature in extruder may create a problem for heat 
sensitive materials. 
 The main advantage is the handling of product is easier because at the outlet of 
the extruder the shape can be adapted to the next processing step without grinding.The 
polymers like Hydroxylpropyl cellulose, Hydroxypropyl cellulose phthalate, Eudragit, 
Celulose acetate phthalate (CAP), Poly vinyl alcohol (PVA), and Hydroxypropyl 
cellulose (HPC) can be used. Leing Wang, et al., have prepared solid dispersion of 
Nitredipine with silica particles using the melt mixing method31. 
c. Solvent method: 
 In this method, the carrier and the active ingredients are dissolved in suitable 
organic solvent. The second step involves the removal of solvent(S) under vacuum. 
When the solvent evaporates, super saturation may occur followed by simultaneous 
precipitation of the constituents resulting in a solid residue. In this formulation the 
scientist has to face two challenges. 
• It is difficult to mix drug and polymer in one solution having different polarity. 
• It is difficult to prevent phase separation during removal of solvent(s). 
• The recovery of solvent from co precipitate takes longer time. 
Example: 
 Ethanol:-5 C and reduced pressure followed by drying for 12h in vaccum 
Methanol / chloroform: 115 C for 1hr 125 C for 25min from Griseofulvin – PEG 6000 
dispersion. 
 Drying at high temperature speeds up the drying process and reduces the time 
available for phase separation. On the other hand, high temperature speeds up the 
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phase separation (example: crystallization) because of the increase in the mobility of 
drug and polymer. 
 For example: Dimethyl sulfoxide (DMSO) has high melting point (190 C)but 
it has very low vapour pressure (0.08 kPa) hence not suitable solvent, but 2-methyl-2-
propanol or tertiary butanol(TBA) is suitable solvent because it has high melting point 
(125 C) and vapor pressure (5.49 kPa). 
Advantages: 
Minimal thermal stress during preparation. 
Reduction in chances of phase separation. 
d. Supercritical fluid method: 
 In this method carbon dioxide is used either as solvent for drug and polymer or 
as an anti-solvent. When carbon dioxide is used as a solvent, the solution mixture of 
carbon dioxide with drug and polymer is sprayed through nozzle into an expansion 
vessel with lower pressure and resulting in formation of particles. As this techniques 
does not involve use of any organic solvent termed as “Solvent free technique” and 
also known as Rapid Expansion of Supercritical Solution (RES). 
1.6.1. Advantages of Solid Dispersion Technology: 
 Single formulation can be used to multiple dose formulation 
 Improves bioavailability of drug. 
 Improves dissolution of poorly water soluble drugs. 
 Controlled release formulations can be formulated. 
1.6.2. Breakthrough in Solid Dispersion Technology: 
Recently, the primary goal of pharmaceutical industry is to discover a new 
chemical entity that would be safe and effective. Initially, because of the limited bulk 
drug supply and accelerated time line would not allow formulator to formulate solid 
dispersion formulations. Even though, the below two recent breakthroughs in the 
formulation of solid dispersion technology have renewed the interest for use in 
commercial development of drug product32,33. 
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The development of technology to fill solid dispersion directly into hard 
gelatin capsules. For example: Chatham prepared PEG-based solid dispersion by 
filling drug-PEG melts in hard gelatin capsules followed by solidification at room 
temperature. The availability of surface-active and self-emulsifying carriers For 
example: Gelucire 44/14, Polysorbate 80. 
The availability of surface-active and self-emulsifying agent may help to 
increase bioavailability of the drug. 
 For example: The bioavailability of ritronavir (solubility<lmcg/ml at pH.2) 
[Norvir®, Abbot Lab] was enhanced by incorporating dispersion into mixture of 
surfaceactive carriers as Gelucire 50/13, Polysorbate 80, and Polyoxyl 35 
castoroil. 
Table No 2: Commercially immediate release Tablets 
Technologies Trade Name Active Ingredient Manufacturer 
Freeze 
Drying 
Feldene Fast Melt Piroxicam Pfizer, USA 
Claritin Red i Tab Loratidine Schering plough, USA 
Maxalt MLT Rizatriptan Merck, USA 
Z Yprexia Olanzepine Eli Lilly, USA 
Pepcid RPD Famotidine Merck, USA 
Zofran ODT Ondansetron Glaxo, UK 
Zooming ZMT Zolmitriptan AstraZeneca, USA 
Zelapar TM Selegilline Amarin,UK 
Disintegrant 
Addition 
Tempra Quicklets Acetaminophen Bristol Myers, USA 
Febrectol Paracetamol Prographarma, France 
Nimulid MDT Nimesulide Panacea Biotech, India 
Torrox MT Rofecoxib Torrent pharma, India 
Olanex Instab Olanzapine Ranbaxy, India 
Romilast Montelukast Ranbaxy, India 
Sugar Based 
Excipient Benadryl Fastmelt 
Diphenhydramine & 
Pseudoephedrine WarnerLambert, USA 
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1.7. ANTI-DIABETIC 34 
 Repaginate is a meglinide analogue used in the treatment of type II Diabetes 
mellitus.  
 It controls high blood sugar levels and helps in preventing kidney damage, 
blindness, nerve problems, loss of limbs, sexual problems & heart complications. This 
should not be used in type I Diabetes mellitus. It is a poorly water soluble drug 
belongs to BCS class II drug with short biological half - life 1hr. Repaglinide was 
enhanced by solid dispersion techniques like 1) drop melt techniques. Repaglinide 
dispersion was selected based on dissolution and formulated as tablet dosage form 
using various diluents and super disintegrates. The final; formulation was selected 
based on the dissolution profile that is formulation with MCC as a diluents and cross 
povidone as a super disintegrants. 
1.7.1. Diabetes mellitus type 2 35,36,37: 
 Diabetes mellitus type 2 (formelycalle non - insulin dependent diabetes 
mellitus(NIDDM), or adult- onset diabetes) is a disorder that is high blood glucose in 
the context of insulin resistance and relative insulin deficiency. It is often initially 
managed by increasing exercise and dietary modification; medications are typically 
needed as the disease progresses. 
1.7.2. Signs and symptoms38 
 Early symptoms may be nothing more than chronic fatigue, generalized weakness 
and malaise 
 Excessive urine production. 
 Excessive thirst and increased fluid intake. 
 Blurred vision  
 Unexplained weight loss. 
 Lethargy. 
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1.7.3.Classification of Antidiabetic agent 
1. Insulin 
2. Oralantidiabetic drugs 
 a) Sulfonylureas 
I. First - generation agents 
 a. Tolbutamide 
b. ACetohexamide 
c.Tolazamide 
d. Chlorpropamide 
II. Second - generation agents 
 a. Glipizide 
 b. Glyburide 
 c. Glimepride 
 d. Gliclazide 
b) Meglitinides 
 I. Repaglinide 
ii. Nateglinide 
c) Biguanides 
I. Metformin 
II. Phenformin 
III. BUformin 
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2. LITERATURE REVIEW 
D. Karthikeyan et al39., investigated the feasibility of formulating a biphasic 
delivery system using mini-tablets in hard gelatin capsules delivering drug with a 
variety of release profiles. Aceclofenac (NSAID analgesic) were chosen as model 
drug. 
Noorana Tehseen et al40., worked on design and characterization of twice daily 
mini-tablets formulation of pregabalin in order to improve the half life and 
bioavailability. 
Carla M. Lopes et al41., developed compressed mini tablets as a biphasic 
delivery system designed for zero-order sustained drug release. The outer layer that 
fills the void spaces between the mini-tablets was formulated to release the drug in a 
very short time (immediate release), while the mini-tablets provided a prolonged 
release. Different composition (HPMC or EC) and number (10 or 21) of mini-tablets 
were used to obtain different drug release rates.  Based on the release kinetic 
parameters calculated, it can be concluded that mini-tablets containing HPMC were 
particularly suitable approaching to zero-order (constant) release over 8 h time 
periods. 
Intender Joshi et al42., developed a once-daily sustained release matrix tablet 
of  repaglinide using sodium alginate as release controlling factor. In order to achieve 
required sustained release profile tablets were compressed using sodium CMC, 
sodium alginate, Magnesium stearate, and PVP. Six different formulation of 
repaglinide were prepared by using different ratio of drug: polymer. The tablet was 
characterized by hardness, wetting time, weight variation and In Vitro Drug Release 
which shows the satisfactory result. All batches of solid matrix tablets were 
satisfactory in terms of dissolution profile. The batches of all formulations, MT5 
batch [Sodium CMC With drug (1:3)] showed more release than the other 
concentration and better results.  
Bhatti et al43 prepared fast dissolving tablets of diazepam and provided it`s 
advantages and evaluation methods. 
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C.MalligarjunaShetty et al44 described the formulation of fast dispersible 
aceclofenac tablets and described the Effect of functionality of super disintegrants. 
Caramella et al45 described the role of swelling property in the disintegration 
process also described how it influences the disintegration process. 
Cirri M et al46 formulated fast dissolving tablets of Glyburide based on ternary 
solid dispersion with PEG6000 and surfactants. 
Sarasija Suresh et al 47prepared mouth dissolving tablets of salbutamol 
sulphate by using sublimable ingredients. Selection of the filter also had an important 
role in deciding of the disintegration time. Evaluation of the tablets  showed that all 
the tablets were found to be within official limits and the disintegration time for the 
formulations ranged from 5s to 4s .Amongest all, the formulation contraining micro 
crystalline cellulose and ammonium bicarbonate showed the least disintegrating time 
of 5s. 
USPTO Patent 2060165782148 described about orally disintegrating tablets for 
per oral administration which disintegrate quickly in the cavity of mouth, in particular 
less than 30 seconds and the process of obtaining them. 
Kaushik D et al49., studied mouth dissolving tablets emerged at an alternative 
to conventional oral dosage forms. Freeze drying, sublimation, spray drying, 
disintegrant addition, tablet moulding and use of sugar-based excipients are the 
techniques available for the formulation of mouth dissolving tablets. Despite the 
different mechanisms involved in these techniques, the aim is, to provide the tablet 
that quickly disintegrates or dissolves upon contact with saliva and also provides a 
god mouth feel. 
Zhao et al50 described the development of disintegrating functionality test for 
super disintegrants, also provides methods to test the efficiency of superdisintegrants. 
Koizumi et al 51, described about rapidly saliva tablets using sublimation 
technique. Compressed tablets of mannitol did not dissolve in water due to the low 
porosity. To increase the porosity of tablets sublimation was done. Tablets were 
prepared by direct compression containing mannitol and camphor. A high porosity 
was achieved due to formation of many pores due to camphor sublimation. The 
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compressed tablets have high porosity (approximately 30%) rapidly dissolved within 
15 seconds in saliva. 
Combo P et al52 described about disintegration force, showed disintegration 
force is a new formulation parameter. 
D.P.Venkadesh et al 53formulated taste masked orodispersible tablets of 
ambroxxol hydrochloride. 
Ferrari F et al54 provided the information about influences of porosity and 
solubility of disintegrant in tablets. 
Caramella et al 55 described the role of swelling property in the disintegration 
process also described how it influences the disintegration process. 
Jeevana Jyothi et al56 developed immediate release tablets of glibenclamide 
using crosspovidone and its Kneading Mixture. 
M M Patel et al 57 prepared rapid disintegrating tablets of valdecoxib by using 
various superdisintegrants following direct compression technique. 
Martin et al58., reviewed the cyclodextrin and their uses. It provides 
information regarding the history preparation, complex formation of cyclodetrins and 
industrial applications. 
Pisal et al 59 formulated and evaluated tasteless complexes of ciprofloxacin 
with Iodine 234. Studies showed that complication affected by pH, but temperature 
not affected. Volunteers rated the complex as tasteless. 
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3. AIM AND OBJECTIVE 
 The aim of the present work is to investigate the possibility of obtaining 
immediate release tablet of repaglinide with improved dissolution using Solid 
dispersion technique. 
 Basic goals in the immediate release tablets are to increase patient compliance, 
ease of administration, safety and appropriate dosing. Orally disintegrating 
formulations are provide benefits for pharmaceutical companies like lifecycle 
management , line extension, market expansion, cost effective drug development 
programs. 
          Immediate release tablet has perceived faster onset of action. repaglinide is a 
white or half white powder, relatively insoluble in water. It is a class 2 drug according 
to BCS Classification Solubility and dissolution was improved by formulating solid 
dispersion. The advantage of this delivery system, in the present study were made to 
formulate immediate release tablet repaglinide, which is useful to reduce sudden 
increased glucose level in the treatment of non- insulin dependent diabetes mellitus 
(NIDDM). 
 The direct compression was used to compress the tablets as it is easy way to 
manufacture tablets. Conventional equipments, commonly available excipients and 
limited number of processing steps are involved in direct compression and so 
manufacturing cost is low. Tablets produced by direct compression are relatively 
strong and hardness and have less friability. 
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4. PLAN OF WORK 
Stage – 1 
 Literature Survey 
 Selection of Drug and Excipients 
Stage - 2 
Preformulation Studies 
 Evaluation of Physical Parameters of repaglinide  
 Drug Excipients Compatibility study 
 Construction of standard curve 
Stage – 3 
 Preparation of Solid Dispersion and Physical Mixture 
 Characterization of Solid Dispersion and Physical Mixture 
Stage – 4 
 Preparation And Evaluation of Natural Superdisintegarants  
Stage – 5 
Precompression Parameters 
 Formulation of Immediate Release Tablets With Different super  Disintegrants 
Stage – 6 
       Evaluation of Immediate Tablets.  
 Weight variation 
 Friability 
 Thickness 
 Hardness 
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 disintegration  
 Wetting time  
 Uniformity of dispersion  
 Water absorption ratio 
 Assay 
 In-vitro dissolution study 
Stage – 7 
 Stability Study of optimised formulaiton as per ICH Guidelines 
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5. PROFILES 
5.1. DRUG PROFILE: 
REPAGLINIDE: 
PRANDIN® (repaglinide) is an oral blood glucose-lowering drug of the 
meglitinide class used in the management of type 2 diabetes mellitus (also known as 
non-insulin dependent diabetes mellitus or NIDDM). 
CHEMICAL NAME: 
Repaglinide, S (+) 2-ethoxy-4(2((3-methyl-1-(2-(1-piperidinyl) phenyl)-butyl) 
amino)-2-oxoethyl) benzoic acid, is chemically unrelated to the oral sulfonylurea 
insulin secretagogues. 
Chemical Structure:  
The structural formula is as shown below: 
 
Molecular Weight: 452.6 
Category:     (ß) cells in the pancreatic islets. 
Description:   white to off – white. 
Storage:  Do not store above 25° C (77° F). Protect from moisture. Keep bottles 
tightly closed.   Dispense in tight containers with safety closures. 
Mechanism of Action 
Repaglinide lowers blood glucose levels by stimulating the release of insulin 
from the pancreas. This action is dependent upon functioning beta (ß) cells in the 
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pancreatic islets. Insulin release is glucose-dependent and diminishes at low glucose 
concentrations. 
Repaglinide closes ATP-dependent potassium channels in the ß-cell 
membrane by binding at characterizable sites. This potassium channel blockade 
depolarizes the ß-cell, which leads to an opening of calcium channels. The resulting 
increased calcium influx induces insulin secretion. The ion channel mechanism is 
highly tissue selective with low affinity for heart and skeletal muscle. 
Pharmacokinetics 
Absorption: 
After oral administration, repaglinide is rapidly and completely absorbed from 
the gastrointestinal tract. After single and multiple oral doses in healthy subjects or in 
patients, peak plasma drug levels (Cmax) occur within 1 hour (Tmax). Repaglinide is 
rapidly eliminated from the blood stream with a half-life of approximately 1 hour. The 
mean absolute bioavailability is 56%. When repaglinide was given with food, the 
mean Tmax was not changed, but the mean Cmax and AUC (area under the 
time/plasma concentration curve) were decreased 20% and 12.4%, respectively. 
Distribution: 
After intravenous (IV) dosing in healthy subjects, the volume of distribution at 
steady state (Vss) was 31 L, and the total body clearance (CL) was 38 L/h. Protein 
binding and binding to human serum albumin was greater than 98%. 
Metabolism: 
Repaglinide is completely metabolized by oxidative biotransformation and 
direct conjugation with glucuronic acid after either an IV or oral dose. The major 
metabolites are an oxidized dicarboxylic acid (M2), the aromatic amine (M1), and the 
acyl glucuronide (M7). The cytochrome P-450 enzyme system, specifically 2C8 and 
3A4, have been shown to be involved in the N-dealkylation of repaglinide to M2 and 
the further oxidation to M1. Metabolites do not contribute to the glucose-lowering 
effect of repaglinide. 
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Excretion: 
Within 96 hours after dosing with 14C-repaglinide as a single, oral dose, 
approximately 90% of the radiolabel was recovered in the feces and approximately 
8% in the urine. Only 0.1% of the dose is cleared in the urine as parent compound. 
The major metabolite (M2) accounted for 60% of the administered dose. Less than 
2% of parent drug was recovered in feces.  
It indicate that repaglinide did not accumulate in serum. Clearance of oral 
repaglinide did not change over the 0.5 - 4 mg dose range, indicating a linear 
relationship between dose and plasma drug levels. 
Variability of Exposure: 
Repaglinide AUC after multiple doses of 0.25 to 4 mg with each meal varies 
over a wide range. The intra-individual and inter-individual coefficients of variation 
were 36% and 69%, respectively. AUC over the therapeutic dose range included 69 to 
1005 ng/mL*hr, but AUC exposure up to 5417 ng/mL*hr was reached in dose 
escalation studies without apparent adverse consequent 
5.2.EXCIPIENT PROFILE: 
CROSS POVIDONE60 
Synonyms : Crosslinkedpovidone ; EI 202 ; Kollidon CL ; Kollidon CL-
M;polyplasdon XL 10 ; Polyvinyl poly pyrrolidone ; PVPP ; 
1-vinyl -2- pyrrolidone homopolymeress or nearly odourless 
hygroscopic powder. 
Description : Crospovidone is a white to creamy white finely devided, free 
Flowing practically tasteless, odorless 
Chemical name : 1-ethenyl -2 – pyrrolidone homopolymer. 
Molecular weight : >1000000 
Functional 
category 
: Tablet disintegrant 
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Applications in Pharmaceutical Formulation 
Cross povidone is a water –insoluble tablet disintegrant and dissolution agent 
used at 2-5% concentration in tablet prepared by direct compression method (1-6). It 
rapidly exibit high capillary activity and pronounced hydration capacity, with little 
tendency to form gels. Studies suggest that the particle size of crospovidone strongly 
influences disintegration of analgesic tablets  
SODIUM STARCH GLYCOLATE60 
Synonyms : Primojel; Starch carboxy Methyl ether, sodium salt, Tablo; 
Description : Tasteless, free flowing powder. The PhEur 2005 states that it 
consist of oval or spherical granules, 30-100 um in diameter, 
with some less spherical granules ranging from 10-35um in 
diameter. 
Chemical name : Sodium carboxy methyl starch. 
Molecular weight : 5 X 10 5 -1 
Functional category : Tablet and capsule disintegrant. 
 
Applications in Pharmaceutical Formulation  
Sodium starch glycolate is widely used in oral pharmaceuticals as a 
disintegrant in capsule and tablet formulations. It is commonly used in tablets 
prepared by either direct compression or wet granulation process. The usual 
concentration employed in a formulation is between 2% and 8% with the optimum 
concentration about 4% although in many cases 2% is sufficient. Disintegration occurs 
by rapid uptake of water followed by rapid and enormous swelling. 
Although the effectiveness of many disintegrant is affected both presence of 
hydrophobic excipients such as lubricant the disintegrant efficiency of sodium starch 
glycolate is unimpaired increasing the tablet compression pressure also appears to 
have no effect on disintegration time. Sodium starch glycolate has also been 
investigated for use as a suspending vehicle.  
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CARBOXY METHYL CELLULOSE CALCIUM60 
Synonyms : Calcium CMC ; ECG 505 ; Nymcel ZSC ; Calcium Carboxy 
methyl cellulose 
Description : It occurs as a white to yellowish- white hygroscopic fine 
powder 
Chemical name : Cellulose, carboxy methyl ether, calcium salt 
Functional 
category 
: Stabilizing agent, suspending agent, tablet and capsule 
disintegrant; tablet binder; viscosity increasing agent Water 
Abosrbing agent. 
 
Application in Pharmaceutical Formulation 
It used as binder, diluents and disintegrant. It is an effective disintegrant as it 
swells to several times it’s original bulk on conduct with water. Concentration up to 
15 % w/w may be used in tablet formulations; above this concentration, tablet 
hardness is reduced. 
It is also used as suspending or viscosity increasing agent in oral and topical 
formulations. And also used in modern wound dressings for it’s water absorption, 
retension and hemostatic properties. 
SODIUM STEARYL FUMERATE60 
Synonyms : Fumeric acid, Otadecyl ester sodium salt; Pruv ; Sodium  
monosrearylfumerate. 
Description : Sodium stearylfumerate is a fine white powder with 
agglomerates of flat, circular shaped particles. 
Chemical name : 2-butenedioic acid, monooctadecyl ester, sodium salt. 
Molecular weight : 390.5 
Functional category : Tablet and capsule lubricant. 
Applications in Pharmaceutical Formulation 
Sodium stearylfumerate is used as lubricant, in capsule and tablet formulations 
at 0.5 – 2.0 % w/w concentration. It is also used in certain food applications 
conditioning or stabilizing agent in various backery Products, flour-thickened foods, 
dehydrated potatos and processed cereal up to 0.2-1.0 % by weight of the food. 
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TALC 61 
Synonyms : talc ; E 55 3 b; hydrous magnesium calcium silicate ; 
hydrous magnesium Silicate; magnesium hydrogen 
metasilicate; Magsilosmanthus; magsil star; powdered talc; 
purified French chalk; Purtalc ; soapstone; steatite; superior 
Description : Talc is very fine to grayish –white, odorless, impalatable,  
unctuous, crystalline powder. It adheres readily to the skin 
and is soft to touch and free from grittiness. 
Chemical name : Talc 
Functional category : Anticaking agent; glidant; tablet and capsule diluents; 
 
Applications in pharmaceutical formulation 
Talc was once widely used in oral solid dosage formulations as a lubricant and 
diluent although today It is less commonly used. It is widely used as dissolution 
retardant in the development of controlled release product. Talc is used as a lubricant 
in tablet formulations; in novel powder coating for extended-release pellets; and as an 
adsorbent. 
In topical preparations, talc is used as a dusting powder, although it should not 
be used to dust. Surgical gloves. As it is a natural material it may contain 
microorganisms and should be sterilized when used as dusting powder. Talc used to 
clarify liquids and is also used in cosmetics and food products, mainly for it’s 
lubricant properties 
POLYETHYLENE GLYCOL 600060 
Synonyms : Breox peg; carbowax; hodag peg; lutrol E; PEG: polyethylene 
glycol. 
Description : Polyethylene glycols grades 6000 and above are available as 
free-flowing milled powders, colorless or slightly yellow 
colured. They have a slight, but characteristic odour and a 
bitter, slightly burning taste. 
Chemical name : ά-hydro-ω- hydro- poly (oxy-1, 2- ethane diyl) and [25322-
68-3] 
Molecular weight: : 5000 – 7000 (average molecular weight) 
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Typical properties: 
1. Density; 1.15–1.21 g/cm3 at 25°C. 
2. Melting Point: 55–63°C 
3. pH (5% w/v solution): 4.0-7.0. 
4. Hydroxyl value: 16–22. 
Incompatibilities: 
All grades can exhibit some oxidizing activity due to the presence of peroxide 
impurities and some secondary product formed by auto- oxidation. Solid polyethylene 
glycols grades may be incompatible with some colour. 
Safety: 
Nontoxic and non-irritant material, when administered topically may cause 
stringing. 
Application in pharmaceutical formulation: 
Polyethylene glycols can also be used to enhance the aqueous solubility or 
dissolution characteristics of poorly soluble compounds by making solid dispersions 
with an appropriate polyethylene glycol. Animal studies have also been performed 
using polyethylene glycols as solvents for steroids in osmotic pumps. 
MICROCRYSTALLINE CELLULOSE60 
Nonproprietary Names: 
• BP: Microcrystalline cellulose 
• JP: Microcrystalline cellulose 
• PhEur: Cellulosummicrocristallinum 
• USPNF: Microcrystalline cellulose 
Synonyms:     
Cellulose gel;; crystalline cellulose; E460;; Fibrocel;; Tabulose. 
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Chemical Name and CAS Registry Number:
Cellulose [9004
Empirical Formula and Molecular Weight:
(C6H10O5)n ≈36
where n ≈ 220.
Structural Formula: 
Functional Category:
Adsorbent; suspending agent; tablet and capsule diluents; tablet disintegrant.
Applications in Pharmaceutical Formulation or Technology:
Microcrystalline cel
binder/diluents in oral tablet and capsule formulations where it is used in both wet
granulation and direct
binder/diluents (20–90%), microcrystalli
disintegrant (5–15%) properties that make it useful in tableting.
Description: 
Microcrystalline cellulose is purified, partially depolymerized cellulose that 
occurs as a white, odorless, tasteless, crystalline powde
particles. It is commercially available in different particle sizes and moisture grades 
that have different properties and applications.
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Density (bulk) 
• 0.337 g/cm3; 
• 0.32 g/cm3 for Avicel PH-101; 0.29 g/cm3 for Emcocel 90M; 0.29 g/cm3 for 
VivaPur 101. 
Density (tapped) : 
• 0.478 g/cm3; 
• 0.45 g/cm3 for Avicel PH-101; 
• 0.35 g/cm3 for Emcocel 90M.  
Density (true): 
• 1.512–1.668 g/cm3 
Melting point: 
Chars at 260–270°C. 
Solubility: 
Slightly soluble in 5 % w/v sodium hydroxide solution; practically insoluble in 
water, dilute acids, and most organic solvents. 
Stability and Storage Conditions: 
Microcrystalline cellulose is a stable though hygroscopic material. The bulk 
material should be stored in a well-closed container in a cool, dry place. 
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6. MATERIALS AND METHODS 
MATERIALS USED 
List of Materials used for the research work was given in table by: 
TABLE NO. 3 
INGREDIENTS SUPPLIERS 
Repaglinide Microlabs Ltd,Hosur 
PEG6000 MicrolabsLtd,Hosur 
Micro crystalline cellulose Lobachemi,Mumbai 
Sodium Starch Glycolate Research lab fine chem, Mumbai 
Cross Povidone Research lab fine chem, Mumbai 
Sodium alginate Lobachemi,Mumbai 
Talc Lobachemi,Mumbai 
Aspartame Bangalore antibiotics &Biological, Salem 
Methanol Himmedialab,Mumbai 
Aerosil Lobachem. Mumbai 
Hcl Microlab,Mumbai 
 
TABLE NO.4 
List of Instrument Used  
Name of Instrument Manufacturing Company 
Digital Balance Shimadzu Corporation Japan 
Magnetic stirrer Remiequipments 
Hot air oven In lab equipments, chenai 
Orbit Shaker Lab India 
Proton Pump Mini Single Punch Proton 
Hardness tester Tab machines 
Friability tester Roche Friabilator 
Vernier caliper Mituyoko Japan 
Dissolution Apparatus Lab India Disso 2000 
UV Visible spectrophotometer Lab India 
FT IR Spectrometer Bruker Germany 
Disintegration Rolex 
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6.1 PRE-FORMULATION STUDIES62: 
Preformulation may be described as a phase of the research and development 
process where the formulation scientist characterizes the physical, chemical and 
mechanical properties of new drug substances, in order to develop stable, safe and 
effective dosage forms. 
6.1.1 Organoleptic properties: 
Appearance 
Transferred approximately 2gm of the sample on a white paper spreaded 
uniformly and examined visually. 
Colour: a small quantity of pure repaglinide powder was taken in a butter paper and 
viewed in well illuminated place. 
Taste and odour: very less quantity of repaglinide was used to get taste with the help 
of tongue as well as smelled to get the odour. 
6.1.2 Angle of repose:  
Angle of repose has been defined as the maximum angle possible between the 
surface of pile of powder and horizontal plane. The angle of repose for the granules of 
each formulation was determined by the funnel method. The prepared granules were 
allowed to flow out of the funnel orifice fixed at a height of 2 cm from the surface on 
a plane paper kept on the horizontal platform. The gradual addition of the granules 
from the funnel mouth forms a pile of granules at the surface this is continued until 
the pile touches the stem tip of the funnel. A rough circle is drawn around the pile 
base and the radius of the granule cone was measured. 
Angle of repose was then calculated with the use of the following formula: 
tanθ = h / r 
Where, θ = angle of repose, h= height of the pile, r = average radius of the powder 
cone. 
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Limits: 
TABLE NO. 5 
Angle of repose Flow property 
<25o Excellent 
25-30 o Good 
30-40 o Passable 
>40 o Very poor 
 
6.1.3: DETERMINATION OF DENSITIES 
Bulk Density:      Bulk density is defined as the mass of the powder divided by 
the bulk volume. Bulk density largely depends on particle shape, as the particle 
become more spherical in shape, bulk density was increased. In addition as the 
granule size increases bulk density decreases. 
METHODS: 
Bulk density of the sample was determined by pouring gently 10g of sample 
through a glass funnel into a 50ml graduated cylinder. The volume occupied by the 
sample was recorded. The bulk density will be calculated as follows: 
Bulk Density (g/ml) = Weight of sample in grams Volume occupied by the 
sample. 
TAPPED DENSITY:  
 10 grams of sample was being poured gently through a glass funnel into a 
50ml graduated cylinder. The cylinder will be tapped from height of 2 inches until a 
constant volume will be obtained. Volume occupied by the sample after tapping will 
be recorded and tapped density will be calculated as follows: 
Tapped Density (grams/ml) = Weight of sample in grams Volume occupied by the 
sample. 
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6.1.4.Measurement of Powder Compressibility:
Based on the apparent bulk and the tapped density, the percentage co
bulk was determined by the following formula
Compressibility index
Where, Vf = final tapped volum
Limits: 
S. No. 
1 
2 
3 
4 
5 
6 
Where, Vf = final tapped volume, Vo = initial un tapped volume
6.1.5 LOSS ON DRYING
Determine on 1 g by drying in an oven at 100°C to 105°C for 3 hours. Mixed 
and accurately weighed the substance to be tested. Tare a glass stopper, shallow 
weighing bottle that has been dried for 30 minutes under the same conditions to be 
employed in the determination. Weighed the empty bottle (W
bottle, replace the cover, and accurately weighed the empty bottle with contents (W
By gentle, sidewise shaking, distributed the sample as evenly as practicable to a depth 
of about 5 mm. placed
the specified temperature in desicator before weighing. Weighed the bottle (W
difference between successive weights should not less than 0.3%.
 Materials and Metho
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: 
e, Vo = initial un tapped volume
TABLE NO.6 
Compressibility index Flow 
5-12 Free flow 
12-16 Good flow 
18-21 Fair 
23-25 Poor 
33-38 Verypoor 
>40 Extremely poor
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The loss on drying is calculated by the formula: 
%    
	 
 
	 
 
 100 
 Where, W1 = Weight of empty weighing bottle 
  W2 = Weight of weighing bottle + sample 
 W3 = Weight of weighing bottle + dried sample 
6.1.6 SOLUBILITY ANALYSIS : 
Solubility is important pre-formulation parameter because it affects the 
dissolution of drug, bio availability of drug, less soluble in water, solubility of 
repaglinide was determined in methanol, ethanol, dimethyl fluoride methylchloride, 
0.1NHCl. Solubility studies were performed by taking excess amount of repaglinide 
in different beakers containing the solvent. 
6.1.7. PH  
 Weighed and transferred accurately about 1.0 g of sample in 20 ml clean and 
dried volumetric flask dissolved in methanol free water and made up the volume to 20 
ml with the same solvent, mixed. Determined the pH of freshly prepared solution by 
using recalibrated pH meter. 
6.1.8.ASSAY  
 Weighed accurately 10mg of repaglinide sample and added to 100 ml 
volumetric flask. Added 1ml of methanol mixed for 10 minutes added 60ml of 0.1 N 
Hydrochloric acid and dissolved it. Made up the volume to 100ml with 0.1 N 
Hydrochloric acid. Took 10ml and diluted to 100ml with 0.1 N HCL. Took 1ml and 
diluted to 10 ml with 0.1 N HCL, absorbance measured at 283nm. 
6.2 DRUG-EXCIPIENT COMPATIBILITY STUDY BY FTIR 
Infra red spectroscopy is one of the most widely used tools for purity analysis of drugs 
in pharmaceutical Industry. Fourier Transform IR spectra were recorded using bruker 
Germany. IR spectrophotometer. KBr powder was used to prepare pellet for sampling. 
The scanning range was 4000- 40cm 
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6.3 PREPARATION OF STANDARD CURVE 
The calibration curve is based on the spectrophotometry. The maximum 
absorption was observed at 283nm.  
The Standard solution in repaglinide in pH acetate buffer 10mg of repagilinde 
is accurately weighed and dissolved in 10ml containing methanol in a volumetricflask. 
The various concentrations of repaglinide prepared are 10, 20, 30, 40, 50, 60,  ug/ml. 
The absorbance of various solutions of repaglinide are determined 
spectrophotometricaly at 283nm employing UV double beam spectrophotometer using 
acetate buffer of pH. 
6.4 PREPARATION OF SOLID DISPERSION AND PHYSICAL MIXTURE63 : 
6.4.1. Solid dispersions prepared by melting the carrier  
Solid dispersions (SDs) preparations containing different weight ratios of 
repaglinide in PEG6000 (1:1, 1:3, 1:5) were prepared by the melting method. 
repaglinide was added to the melted PEG 6000 at 75oC and the resulting homogenous 
preparation was rapidly cooled in a freezing mixture of ice and sodium chloride, and 
stored in desiccators for 24h.Subsequently, the dispersion was ground in a mortar and 
sieved through 100# 
6.4.2.Physical Mixture 
Physical mixture (PMs) having the same weight ratios were prepared by 
thoroughly mixing appropriate amounts of repaglinide and PEG 6000 in a mortar until 
a homogenous mixture was obtained. The resulting mixture were sieved through a 
100# sieve and denoted as PM. 
6.5 Characterization of solid dispersions of repaglinide with PEG 600064 
6.5.1 Drug content 
About 10mg of drug equivalent of physical mixture and solid dispersion 
(theoretical) were weighed accurately and transferred to 50ml volumetric flask to 
which 10ml methanol was added and sonicated for 15min and volume was made up 
with methanol. From this stock solution further dilution were done and assayed using 
ultraviolet spectrophotometer measured at 283nm. 
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6.5.2 Phase-Solubility Study 
Phase-solubility studies were carried out to evaluate the possible solubilizing 
effect of the carrier by adding an excess amount of drug to flask containing 10ml of 
aquous solutions containing increasing concentrations of PEG6000.The flask were 
placed in a mechanical shaker at 75rpm and room temperature for 24hour.After 24 
Hours the solutions were filtered and analysed by UV-Spectrophotometer at 283nm.. 
6.5.3 Dissolution Studies: 
Dissolution studies of repaglinide in powder form, SDs, and PMs were 
performed by using the USP type II paddle apparatus at the paddle rotation speed of 
75 rpm in 900ml of pH 5 acetate buffers as a dissolution medium at 37±0.5 °C. The 
SDs or PMs Equivalent to 2mg of repaglinide was weighed using a digital balance 
and added into the dissolution medium. At the specified times (every 10 min for 2 
hours), 10ml samples were withdrawn by using syringe filter (0.45 µm) and then 
assayed for repaglinide content by measuring the absorbance at 283 nm using a UV-
Visible spectrophotometer. Fresh medium (10ml), which was prewarmed at 37 °C, 
was added to the dissolution medium after each sampling to maintain its constant 
volume throughout the test.  
6.5.4. Fourier transforms IR spectroscopy: 
Fourier-transform infrared (FT-IR) spectra were obtained by using Bruker 
Germany FTIR. The samples (repaglinide or SDs or PMs) were previously ground 
and mixed thoroughly with potassium bromide, an infrared transparent matrix, at 1:5 
(Sample/KBr) ratio, respectively. The KBr discs were prepared by compressing the 
powders at a pressure of 5 tons for 5 min in a hydraulic press.  
6.6. Preparation of natural superdisintegrants (plantago ovata seed powder, 
mucilage and husk powder)65: 
 The powder of seeds and husk were prepared by an automatic grinder and 
sieved (#80). Then it stored in a dedicator until use .For isolation of seed mucilage, the 
cleaned seeds of Plantagoovata were soaked in distilled water 48 hrs and then boiled 
few minutes so that mucilage was completely released in to water. This material 
squeezed through muslin cloth for filtering and separating out the marc. Then an equal 
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volume of acetone was added to the filtrate so as to precipitate the mucilage .The 
mucilage was dried in oven (less than 60oC), powdered, sieved (# 80) and stored in 
desiccators until use. 
 The natural super disintegrants were evaluated for their physicochemical 
properties. The swelling index is calculated, it is the volume in milliliters that is 
occupied by 1g of drug or any substance after it has swollen in an aqueous liquid for4 
hr. The physical mixture of drug complex with this super disintegrants was allowed to 
stand for 7 days and the assay of drug was performed for compatability studies.  
 Preparation of the prepared natural super disintegrants were evaluated for 
swelling factor, bulk density, tapped density, angle of repose. Angle of reposewere 
calculated according to the formula procedure in 6.1.4 bulk density and tapped density 
were found out using the procedure given compressibility and hausner’s ratio were 
found out according to the formula 6.1.4. 
6.7. FORMULATION OF IMMEDIATE RELEASE TABLETS OF 
REPAGLINIDE.66 
 Different repaglinide Immediate Release Tablets were prepared according to 
the proportions given in the table no 9. The raw materials passed through a screen (# 
60). Prior to mixing powdered separately the repaglinide Solid dispersion, and 
weighed the amount equivalent to 10 mg repaglinide, was mixed with other excipients 
and compressed proton mini press tablet punching machine.  All formulation prepared 
according to the following formulation table. 
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FORMULATION OF IMMEDIATE RELEASE TABLET 
Table No - 7 
S. 
No. 
Ingredient 
Name F1 F2 F3 F4 F5 F6 F7 F8 F9 F10 F11 F12 
1 
1:5 Solid 
Dispersion 
equivalent to 
2mg 
Repaglinide 
10 10 10 10 10 10 10 10 10 10 10 10 
2 
Micro 
crystalline 
Cellulose 
92 92 92 92 92 92 92 92 92 92 92 92 
3 Mannitol 80.0 78.0 80.0 78.0 80.0 78.0 80.0 78.0 80.0 78.0 80.0 78.0 
4 Isphagol Mucilage 10 12.0 - - - - - - - - - - 
5 IsphagolPowder - - 10.0 12.0 - - - - - - - - 
6 Iphagol husk powder - - - - 10.0 120 - - - - - - 
7 Cross Povidone - - - - - - 10.0 12.0 - - - - 
8 CMC  - - - - - - - - - 10.0 12.0 
9 SSG - - - - - - - - 10.0 12.0 - - 
10 Talc 2 2 2 2 2 2 2 2 2 2 2 2 
11 Aspartame 1 1 1 1 1 1 1 1 1 1 1 1 
12 Aerosil 4.0 4.0 4.0 4.0 4.0 4.0 4.0 4.0 4.0 4.0 4.0 4.0 
13 Orange Flavour 1 1 1 1 1 1 1 1 1 1 1 1 
 Total weight 200 200 200 200 200 200 200 200 200 200 200 200 
 
6.8. Evaluation of Immediate Release Tablet67: 
6.8.1 PHYSICALAPPEARANCE 
 Prepared immediate release Tablets were evaluated for the smoothness and 
absence of cracks, chips and other undesirable characteristics 
6.8.2 WEIGHT VARIATION 
 Twenty tablets were randomly selected and weighed to determine the average 
weight and were compared with individual tablet weight. The percentage weight 
variation was calculated. As per Indian Pharmacopoeia specification, tablet with an 
average weight between 80 – 250 mg, percentage deviation should not more than ±o.5 
% and the tablet with an average weight more than 250 mg should not be more than ± 
10 %. 
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                Tablet weight – Average weight 
% Deviation=                                                            X 100 
                              Tablet weight 
6.8.3 FRIABILITY68 
 Friability of the tablets was checked by Roche friabilator. In this device, 
tablets subjected to combined effects of abration and shock by utilizing a plastic 
chamber that revolves at 75 rpm, dropping the tablets at a distance of6 inches in each 
revolution. Pre weighed tablets were placed in friabilator, which was then operated for 
100revolutions. The tablets were dusted and reweighed. 
                             W0 – W1 
                   F=                           X 100 
                                W0 
W0 = initial weight,W1 =final weight 
6.8.4 THICKNESS 
 The thicknesses were measured using vernier caliper and values were 
tabulated. Three tablets of each batch were measured. Average and standard deviation 
was calculated.  
6.8.5 HARDNESS 
 Monsanto hardness tester was used for the determination of hardness. For each 
formulation 3 tablets were determined.  
6.8.6 DISINTEGRATION TIME69 
 A disintegration time of6 tablet from each formulation was determined by 
using USP disintegration apparatus. Disintegration test was carried out in 900ml 
buffer pH 6.8at 37 ± 2 0Cand apparatus operated for 3 minutes, six tablets were taken 
and one tablet was introduced in each tube, disc was placed and basket and the 
disintegration time in seconds was noted.  
6.8.7 WETTING TIME 
 This is carried out as a measure of hydrophilicity of tablets. Wetting time is a 
length of time required to wet the tablet. A piece of tissue paper (12 x 10.75) was 
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folded twice was placed in the small Petri dish (I.D 6.5cm ) containing 6 ml of buffer 
pH 6.8 simulated to salivary pH, tablet was placed on the paper and time for complete 
wetting was measured. Three trials of each batch were performed and standard 
deviation was determined. 
 6.8.8 UNIFORMITY OF DISPERSION TEST 
 Two tablets from each batch were separately kept in 100 ml water and gently 
stirred for 2 minutes. The dispersion was passed through 22 mesh. The tablets were 
considered to pass the test if no residue remained on the screen. 
6.8.9 WATER ABSORPTION RATIO 
 Water absorption ratio, which is important criteria for understanding the 
capacity of disintegrants to swell in the presence of little amount of water. Weight of 
the tablet after and before the test was taken. Water absorption ratio (R) is calculated 
using following formula.  
                                      Wa – Wb  
                        R =                           X 100 
                                           Wb  
Where,  
Wa = weights of the tablets after water absorption test 
Wb = weight of the tablets before water absorption test 
6.8.10 ASSAY70 
STANDARD PREPARATION  
 Weigh accurately 100 ml volumetric flask, dissolved in minimum quantity of 
methanol. The volume made up to 100 ml with 0.1 N hydrochloric acid. Took 10 ml 
of that solution and diluted to 100 ml with 0.1 N hydrochloric acid. Took 1 mlfrom 
that solution and diluted to 10 ml with 0.1 N hydrochloric acid.  
SAMPLE PREPARATION 
 Mixed well and volume made up to 100ml. Filtered the solution and 10 ml of 
this solution diluted to 100 ml. From that took 1ml and diluted to 10 ml. Absorbance 
measured at 283 nm by UV/Visible spectrophotometer.  
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6.8.11 DISSOLUTION STUDIES71 
 Dissolution studies were carried out using USP type II (paddle apparatus) at 
75rpm pH 5 acetate buffer was used as dissolution medium. Temperature was 
maintained at 37 ±0.5 0C. Aliquots of dissolution media was withdrawn at specific 
time intervals and it was filtered. Same quantity of fresh media was replaced. The 
filtered solution was used to determine the estimation of drug content. The 
absorbances were measured at 283 nm by UV/Visible spectophtometer. The test was 
carried out for 30 minutes 
6.8.12 KINETIC STUDY 
 The release data obtained from optimized formulation was studied further for 
the fitness of data in different kinetic models like, zero order, first order, Higuchi’s 
and korsmeyer – Peppa’s. 
6.9 ACCELERATED STABILITY STUDIES 
 Selected formulation were subjected to stability studies as per I.C.H 
guidelines. Following conditions were used for stability testing. 400 C / 75 % RH 
analyzed every month for a period of two months as per I.C.H guidelines. By keeping 
40 ± 20C /RH the formula analyzed every month for a period of 3 months. 
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7. RESULTS AND DISCUSSION 
7.1 Preformulation Studies  
7.1.1 Organlopetic Properties  
These tests were performed as per procedure given in 6.1.1. The results were 
illustrated in table no.8.  
Table No. 8: Organoleptic Properties 
Test Specification/Limits Observations 
Color White to half-white powder White powder 
Odour Odourless Odourless 
 
7.1.2 Loss on Drying  
This test was done as per procedure stated in 6.1.2. The results were 
illustrated in table no.9.  
Table No.9 : Loss on Drying 
Test  Specification/Limits Observations 
Loss on drying  Not more than 0.5% 0.085% 
 
7.1.3 Flow Properties (Angle of repose) 
 It was determined as per procedure given in 6.1.3. The results were 
illustrated in tables No. 10.  
Table No.10: Flow properties 
Material Angle of repose 
Repaglinide 27.85`` 
 
*Average of three determinations 
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7.1.4 Determination of Density 
It was determined as per procedure given in 6.1.4. The results were 
illustrated in table no. 11. 
Table No.11: Density 
Material Bulk Density (gm/ml) Tapped density (gm/ml) 
Repaglinide 0.24 0.35 
 
*Average of three determinations 
7.1.5. Powder compressibility  
It was determined as per procedure given in 6.1.5. The results were 
illustrated in table no. 12.  
Table No.12: Powder Compressibility 
Materials Compressibility index Hausner ratio 
Repaglinide 14.23% 1.84% 
 
*Average of three determinations 
7.1.6. Solubility  
It was determined as per procedure given in 6.1.6. The results were 
illustrated in table no. 13.  
Table No.13: Solubility 
Test Specification Result 
Solubility in water, Methanol, 
Methylene chloride. 
Practically insoluble  in water, freely 
soluble in methylene chloride, 
soluble in methanol 
Complies 
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7.1.7 pH of the solutions  
pH of the solution was determined as per procedure given in 6.1.7. The 
results were illustrated in table no. 14.  
Table No.14: pH 
Test Specification Observation 
pH 5.5 5 
 
7.1.8. Assay  
It was determined as per procedure given in 6.1.8. The results were 
illustrated in table no. 15.   
Table No.15: Assay 
Assay 
Test  Specification  Observation  
Assay  90.8-101.75 % 101.18%  
 
7.2 DRUG EXCIPIENTS COMPATABILITY STUDY BY FTIR; 
 Compatibility study was perfomed using FT-IR spectrophotometer .The IR 
spectrum of pure drug, physical mixture of drug and excipients were studied by 
making a KBr pellet. 
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7.2.1 FTIR Studies  
The spectral details for the drug and physical mixtures are shown as follows 
FT-IR Peak Of Various Components. 
 
Fig.No. 1: IR spectrum of Repaglinide 
 
  
Fig. No. 2: Ispagol Mucilage 
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Fig. No. 3: Ispagol Seed Powder 
 
 
Fig. No. 4: Ispagol Husk Powder 
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Fig. No. 5: IR Spectra of Microcrystalline Cellulose 
 
 
 
Fig. No. 6: IR Spectra of Crospovidone 
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Fig. No. 7: IR Spectra of Croscarmellose Sodium 
 
 
 
Fig. No. 8: IR Spectra of Sodium Starch Glycolate 
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Fig. No. 9: IR Spectra of PEG 6000 
 
 
 
Fig. No. 10: IR Spectra of Repaglinide & Excipient Mixture 
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Table No. 16: 
Characteristic bands Pure drug Physical mixture 
O-H 3103.54cm-¹ 3005.14cm-¹ 
N-H 1599.09cm-¹ 1739.03cm-¹ 
C-O 1108.83cm-¹ 1365.64cm-¹ 
C=C 3005.90 cm-¹ 1477.26cm-1 
C-N 2825.87 cm-¹ 1579.39cm-1 
 
The FT-IR Spectra analysis showed that there is change in percent 
transmittance which may be due to change in crystallinity and there is no 
appearance or disappearance of any characteristics peak of pure drug repaglinide 
and in the physical mixture of drug to polymer, which confirms the absence of 
chemical interaction between drug and polymer. 
7.3. PREPARATION OF STANDARD CURVE 
 A UV spectrophometric method given in IP is used for dissolution samples of 
repaglinide tablet. Absorbance scans of drug is pH5 acetate buffer, showed 
maximum at 283nm, which is selected as the analytical wavelength. Standard curve 
of repaglinide in Calibration curve of repaglinide was determined by plotting 
absorbance versus concentration (µg/ml) at 283nm. The results obtained were as 
follows. 
repaglinide standard calibration curve in pH 5 Acetate buffer at 283 nm 
Table No – 17 : 
Concentration (µg/ml) Absorbance at 283nm 
10 0.121 
20 0.283 
30 0.455 
40 0.651 
50 0.810 
60 0.913 
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Fig. 11 : Calibration curve in pH 5 Acetate buffer at 283 nm 
7.4 PREPARATION OF SOLID DISPERSION AND PHYSICAL MIXTURE  
 As per the method given in 6.4.1 and 6.4.2 solid dispersion and physical 
mixture were prepared. 
7.5 Characterization of solid dispersions of repaglinide with PEG 6000 
7.5.1. Drug content 
It was determined as per procedure given in 6.5.1. The results were 
illustrated in table no. 18.  
Table No. 18: Drug content in physical mixtures and solid dispersions 
Solid dispersion 
(drug to PEG mass 
ratio) 
Drug content 
(%) 
Physical mixture 
(drug to PEG mass 
ratio) 
Drug content 
(%) 
SD 1:1 97.54 PM 1:1 98.05 
SD 1:3 96.25 PM 1:3 97.96 
SD 1:5 98.42 PM 1:5 98.18 
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7.5.2. Phase solubility Study 
It was determined as per procedure given in 6.5.2. The results were 
illustrated below. 
 
Fig. 12 : Solubility diagram of repaglinide in presence of PEG 6000 
Fig no.11 represented the effect of different polymers concentration at 
different temperature on the solubility of repaglinide. The plots of drug solubility 
against the polymer concentration at the investigated temperatures indicated a linear 
relationship between drug solution and polymer concentration. The result shown 
that in both cases, the solubility of repaglinide increased with increasing 
temperature and carrier concentration. 
 Solubility of repaglinide in pure water at 25oC was 0.01 (µg/ml). At the 
highest polymer concentration (10% w/w), the solubility increased approximately 4 
fold for PEG 6000 at 25o. The same tendency was observed for other temperatures. 
7.5.3. Dissolution studies 
It was determined as per procedure given in 6.5.3. The results were 
illustrated in table no. 20.  
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Table No. 20 : In-vitro Dissolution Profile of repaglinide Physical Mixture of 
repaglinide and Solid Dispersion of repaglinide in pH 1.2 Buffers. 
Sr. No. Formulation Percentage drug released after 30 minutes (DR) 
A1 Drug 31.23 ± 2.25 % 
A2 PM 1:1 41.54 ± 2.58 % 
A3 PM 1:2 44.86 ± 2.69% 
A4 PM 1:5 51.12 ± 2.50% 
A5 SD 1;1 87.89 ± 2.25 % 
A6 SD 1:2 93.46 ± 2.35 % 
A7 SD 1:5 98.35 ± 2.76 % 
 
Fig. 12: Comparison of in-vitro dissolution profile of formulation A1-A7 
The percentage release of repaglinide at various time intervals from the 
physical mixtures and solid dispersions made by using various concentration. 
The percentage release of repaglinide at various time intervals from the 
physical mixtures and solid dispersions made by using various concentrations of 
PEG 6000 are shown in Fig.no.11. From table no.20 it is evident that onset of 
dissolution of pure repaglinide is very low, about 31.23% of drug being dissolved 
within 30 min. In the 30 minutes, physical mixtures of PEG 6000 (1:1, 1:2 and 1:5) 
showed 41.54, 44.86 and 51.12% drug release, and 87.89, 93.46, and 98.35 % drug 
release from solid dispersions (1:1, 1:2 and 1:5).SDs of repaglinide with PEG 6000 
considerably enhanced dissolution rates within 30 min compared to pure repaglinide 
and PMs. 
7.5.4 Fourier transforms IR spectroscopy 
It was determined as per procedure given in 6.5.4. The following figures 
were illustrated results.  
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Fig. No. 13: IR Spectra of Repaglinide 
 
 
 
Fig. No. 14: IR Spectra of Solid dispersion 1:1 
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Fig. No. 15: IR Spectra of Physical mixture 1:1 
 
 
Fig. No. 16: IR Spectra of Solid dispersion 1:3 
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Fig. No. 17: IR Spectra of Physical mixture 1:3 
 
 
Fig. No. 18: IR Spectra of Solid dispersion 1:5 
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Fig. No. 19: IR Spectra of physical mixture 1:5 
The IR spectra of SDs and PMs were compared with the standard spectrum 
of repaglinide. IR spectrum of repaglinide was characterized by the absorption of 
carbonyl (C-O) group at 1108.83cm−1. In spectra of SDs and PMs, this band was 
shifted towards higher frequencies at 3005.14 and 2,825.87cm−1 respectively. Also 
the O-H group which is located at 3,103.54 cm−1 from the IR spectrum of 
repaglinide, N-H group at1599.09, C=C group at 3005.90, C-N group at 2825.87  It 
was concluded that there was no well defined chemical interaction between 
repaglinide and PEG 6000 in SDs and in PMs, as no important new peaks could be 
observed. 
7.6. Preparation And Evaluation Of Natural Superdisintegrants 
 Natural super disintegrates were prepared and evaluated according to the 
procedure given in 6.6. 
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Table No. 21 : Preliminary evaluation of natural superdisintegrants 
Parameters Mucilage Seed Powder Husk Powder 
Bulk Density (gm/cm3) 0.96 0.50 1.17 
Tapped Density (gm/Cm3) 1.08 0.91 1.35 
Hausners Ratio 1.083 1.14 1.11 
Compressibility index (%) 6.58 15.37 14.66 
Angle of Repose (o) 25.20 40.36 33.15 
 
7.7. FORMULATION OF REPAGLINIDE IMMEDIATE RELEASE 
TABLET  
According to the formula given in table No. 8, repaglinide immediate release 
tablet were formulated and before formulation precompression parameters were 
evaluated and given in table no. 22. 
Table No : 22 Precompression parameters 
Parameters F1 F2 F3 F4 F5 F6 F7 F8 F9 F10 F11 F12 
Bulk density 0.360 0.370 0.310 0.310 0.32 0.330 0.320 0.350 0.370 0.350 0.330 0.320 
Tapped Density 0.450 0.440 0.430 0.420 0.43 0.440 0.410 0.440 0.44 0.45 0.43 0.41 
% 
Compressibility 15.36 15.07 21.64 20.15 20.85 20.47 16.64 16.56 17.35 18.13 18.81 I7.65 
Hausners Ratio 1.185 1.11 1.25 1.23 1.24 1.21 1.20 1.43 1.17 1.26 1.36 1.26 
Angle of 
Repose 21.26 20.14 24.38 24.45 23.27 23.17 20.37 20.09 21.15 21.29 25.36 24.19 
 
7.8. EVALUATION OF IMMEDIATE RELEASE TABLETS 
7.8.1. TABLET PHYSICAL APPEARANCE 
 The tablets were evaluated for their physical properties like color uniformity, 
presence of cracks, chipping, etc. No undesirable properties were found out. 
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7.8.2. WEIGHT VARIATION TEST 
 It was determined as per procedure given in 6.8.2. The results were illustrated 
in table No. 23.  
7.8.3. FRIABILITY 
 The friability test were carried out according to the procedure given in 6.8.3. 
The result was tabulated in the Table No. 24. 
7.8.4. THICKNESS 
 The thickness was carried out according to the procedure given in 6.8.4. The 
result was tabulated in the table No.23. 
7.8.5. HARDNESS (KG/CM2) 
 The Hardness tests were carried out according to the procedure given in 
6.8.5. The result was tabulated in the table No.23. 
7.8.6. DISINTEGRATION TEST (IN SEC.) 
 It was determined as per procedure given in 6.8.6 the results were illustrated 
in table No.23. The results indicated that the disintegration time of tablets was within 
35seconds. 
7.8.7. WETTING TIME 
 It was determined as per procedure given in 6.8.7 .The results were illustrated 
in table 23. 
7.8.8. TEST FOR UNIFORMITY OF DISPERSION 
 It was determined as per procedure given in 6.8.8. The results were illustrated 
in table No.23.  
7.8.9. WATER ABSORPTION RATIO 
 The test is conducted according to the procedure given in 6.8.9. To measure 
the hydrophilicity of tablets, the results were illustrated in the table No.23. 
7.8.10 ASSAY 
 It was determined according to the procedure given in 6.8.10. The percent 
purity was detrmined by UV method, the results were illustrated in the table No.23. 
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Table No.23: EVALUATION CHART OF TABLET 
S.No Para meter 
Formulation Code 
F1 F2 F3 F4 F5 F6 F7 F8 F9 F10 F11 F12 
1 Weight Variation Test 
198.66 
±0.23 
199.66 
±0.25 
197.66 
±0.39 
200.66 
±0.43 
198.66 
±0.23 
196.66 
±0.49 
198.66 
±0.39 
197.66 
±0.35 
199.66 
±0.23 
198.66 
±0.23 
199.66 
±0.27 
199.66 
±0.23 
2 % Friability 0.26 0.20 0.21 0.30 0.28 0.20 0.23 0.21 0.24 0.32 0.25 0.23 
3 Thickness (mm) 2.58± 
0.01 
2.59± 
0.03 
2.35± 
0.05 
2.30± 
0.02 
2.41± 
0.05 
2.42± 
0.06 
2.42± 
0.02 
2.48± 
0.06 
2.44± 
0.04 
2.43± 
0.05 
2.41± 
0.04 
2.35± 
0.06 
4 Hardness (Kg / cm2) 2.06 
±0.10 
2.06 
±0.09 
2.84 
±0.41 
3.17 
±0.15 
2.91 
±0.18 
2.95 
±0.14 
2.74 
±0.14 
2.79 
±0.31 
2.84 
±0.36 
2.90 
±0.37 
2.91 
±0.39 
2.96 
±0.40 
5 Disintegration Time(sec) 
23.36 
±2.6 
21.05 
±1.5 
27.39 
±2.5 
23.69 
±2.8 
25.63 
±2.4 
26.05 
±3.5 
22.00 
±2.8 
22.05 
±2.5 
28.05 
±2.6 
26.63 
±3.7 
34.68 
±2.9 
34.69 
±2.5 
6 Wetting time (sec) 50.69 
±1.6 
47.69 
±1.9 
63.04 
±2.9 
66.339 
±2.9 
63.36 
±2.6 
57.63 
±2.6 
54.36 
±1.6 
52.69 
±2.7 
52.05 
±2.6 
53.36 
±2.9 
65.39 
±2.5 
63.06 
±2.6 
7 Uniformity of Dispersion Pass Pass Pass Pass Pass Pass Pass Pass Pass Pass Pass Pass 
8 W.A.Ratio (%) 65.46 65.36 73.85 74.07 66.07 67.35 65.34 65.39 66.15 66.93 74.19 73.69 
9 Assay (%) 99.48 100.5 98.34 99.82 99.10 101.41 100.06 100.15 101.21 101.02 100.9 100.4 
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7.5.11 IN-VITRO DISSOLUTION STUDIES 
 Dissolution study carried out according to procedure given in 6.8.11.The 
study or 30 minutes, the results were illustrated in the table below. 
Table No.24: Dissolution profile of formulation F1 
Time In Minute Cummulative Percent Drug Release(%) 
0 0 
5 78.45 
10 80.92 
15 84.76 
20 89.15 
25 93.82 
30 97.92 
 
 
Fig.No. 20. In-vitro dissolution study F1 
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Table No.25: Dissolution profile of formulation F2 
Time in Minute Cummulative Percent Drug Release (%) 
0 0 
5 78.72 
10 81.45 
15 84.50 
20 90.00 
25 94.37 
30 99.50 
 
 
Fig.No. 21. In-vitro dissolution study F2 
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Table No.26: Dissolution profile of formulation F3 
Time in minute Percent Drug Release (%) 
0 0 
5 79.82 
10 82.02 
15 85.03 
20 90.52 
25 94.91 
30 98.75 
 
 
Fig.No. 22. In-vitro dissolution study F3 
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Table No.27: Dissolution profile of formulation F4 
Time in Minute Cumulative Percent Drug Release (%) 
0 0 
5 80.37 
10 82.30 
15 85.85 
20 91.90 
25 94.95 
30 98.23 
 
 
Fig.No. 23. In-vitro dissolution study F4 
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Table No.28: Dissolution profile of formulation F5 
Time in minute Cumulative Percent Drug Release (%) 
0 0 
5 81.47 
10 84.50 
15 86.14 
20 90.10 
25 94.15 
30 98.05 
 
 
Fig.No. 24. In-vitro dissolution study F5 
  
0
20
40
60
80
100
120
0 5 10 15 20 25 30 35
C
u
m
u
la
ti
v
e
 %
 d
ru
g
 r
e
le
a
se
Time (min)
Chapter 7  Results and Discussion 
Dept. of Pharmaceutics 67 J.K.K. Nattraja College of Pharmacy 
Table No.29: Dissolution profile of formulation F6 
Time in minute Cumulative Percent Drug Release (%) 
0 0 
5.0 84.75 
10 86.69 
15 89.15 
20 93.25 
25 97.39 
30 98.87 
 
 
Fig.No. 25. In-vitro dissolution study F6 
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Table No.30: Dissolution profile of formulation F7 
Time in minute Cumulative Percent Drug Release (%) 
0 0 
5.0 82.58 
10 85.05 
15 57.24 
20 90.53 
25 95.73 
30 99.35 
 
 
Fig.No. 26. In-vitro dissolution study F7 
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Table No.31: Dissolution profile of formulation F8 
Time in minute Cumulative Percent Drug Release (%) 
0 0 
5.0 80.37 
10 82.15 
15 85.46 
20 89.11 
25 94.15 
30 99.65 
 
 
Fig.No. 27. In-vitro dissolution study F8 
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Table No.32: Dissolution profile of formulation F9 
Time in minute Percent Drug Release (%) 
0 0 
5.0 83.23 
10 86.17 
15 88.55 
20 92.70 
25 96.05 
30 98.41 
 
 
Fig.No. 28. In-vitro dissolution study F9 
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Table No.33: Dissolution profile of formulation F10 
Time in minute Cumulative Percent Drug Release (%) 
0 0 
5.0 84.76 
10 86.70 
15 89.19 
20 93.29 
25 96.40 
30 97.50 
 
 
Fig.No. 29. In-vitro dissolution study F10 
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Table No.34: Dissolution profile of formulation F11 
Time in minute Cumulative Percent Drug Release (%) 
0 0 
5.0 83.85 
10 86.05 
15 89.24 
20 91.55 
25 95.75 
30 98.35 
 
 
Fig.No. 30. In-vitro dissolution study F11 
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Table No.35: Dissolution profile of formulation F12 
Time in minute Cumulative Percent Drug Release (%) 
0 0 
5.0 83.81 
10 87.17 
15 88.65 
20 92.60 
25 96.15 
30 98.99 
 
 
Fig.No. 31. In-vitro dissolution study F12 
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Table No: 36 Comparative dissolution study F 1 – F 12 . 
Time F1 F2 F3 F4 F5 F6 F7 F8 F9 F10 F11 F12 
0 0 0 0 0 0 0 0 0 0 0 0 0 
5 78.45 78.72 79.82 80.37 81.47 84.75 82.58 80.37 83.23 84.76 83.85 83.81 
10 80.92 81.45 82.02 82.30 84.50 86.69 85.05 82.15 86.17 86.70 86.05 87.17 
15 84.76 84.50 85.03 85.85 86.14 89.15 87.24 85.46 88.55 89.19 89.24 88.65 
20 89.15 90.00 90.52 91.90 90.10 93.25 90.53 89.11 92.70 93.29 91.55 92.60 
25 93.82 94.37 94.91 94.35 94.15 97.39 95.73 94.15 96.05 96.40 95.75 96.15 
30 97.92 99.50 98.75 98.23 98.05 98.87 99.35 99.65 98.41 97.50 98.35 98.99 
 
 
Fig.No. 32. Comparison of In-vitro dissolution profile of formulation F1-F12 
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7.8.12. KINETIC STUDY OF OPTIMIZED FORMULATION  
 In-vitro release data was flatted in different kinetic model and given in table 
37 and figure 33 to 36.  
Table No. 37 Kinetic data of Optimized Fomulation F2 
Time Log time Time  
Cumulative 
% drug 
release 
Log 
cumulative 
% drug 
release 
Cumulative 
% drug 
remained 
Log 
cumulative 
% drug 
remained 
0 0 0 0 0 100 2.00 
5 0.698 2.23 78.72 1.89 21.28 1.32 
10 1.0 3.16 81.45 1.91 18.55 1.26 
15 1.176 3.87 84.50 1.92 15.50 1.19 
20 1.301 4.47 90.00 1.95 10.00 1.00 
25 1.397 5.0 94.37 1.97 5.63 0.75 
30 1.477 5.477 99.50 1.99 0.50 0.30 
 
 
Fig. No. 33 : ZERO ORDER 
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Fig. No. 34 : FIRST ORDER 
 
 
 
Fig. No. 35 : HIGUCHI 
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Fig. No. 36 : KORSEMEYER PEPPAS PLOT 
The above studies showed that the drug release follows first order kinetics. 
7.9. STABILITY STUDY 
Optimized formulation (F2) was subjected to stability studies at 40oc± 
2oc/75% RH ±5 % for 90 days. The product was evaluated for appearance and 
hardness, friability, disintegration. Drug release studies were conducted as per the 
planned scheduled as above. 
7.9.1. Descriptions: 
Table No.38: Description 
Storage 
condition Test Observation Inference 
RT Descriptions No change of color in all 
strengths 
Complies with stability 
condition 
40oC + 2oC/ 
75% RH Descriptions 
No change of color in all 
strengths 
Complies with stability 
condition 
 
7.9.2. Stability parameters of formulation F2 stored at 40oC + 2oC/ 75% RH 
 The results were illustrated in following table no. 39. 
y = -0.266x + 2.038
R² = 0.905
0
0.5
1
1.5
2
2.5
0 1 2 3 4 5 6
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Table No.39: 
Sr. 
No. Parameters Initial 30 days 60 days 90 days 
1 % Friability 0.20 0.27 0.270 0.273 
2 Hardness (kg / cm2)      2.6 2.5 3.1 3.2 
3 Drug Content (%) 100.01 99.10 98.51 98.21 
4 In-Vitro Disin. 
Time(Sec) 21.05 21.15 23.24 24.11 
 
 All results complies with the stability condition 
7.9.3. In-vitro Dissolution study  
 It was done as per procedure given in material and method part. The results were 
illustrated in following table no. 45. 
Storage Condition at 40oC + 2oC 
Table No.40: In-vitro dissolution study 
Formulation 
(F2) 
Percentage Drug Release After 30 minutes 
Initial (0Days) 30 Days 60 Days 90 Days 
99.50 99.60 98.54 98.60 
 
The results showed that there was no significant change in physical and 
chemical parameter of the tablet, hence the formulation was found to be stable. 
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Fig. No. 37: In-vitro dissolution study F2 dissolution studies 
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8. SUMMARY AND CONCLUSION 
SUMMARY 
 In the present study immediate release drug delivery system of repaglinide 
were successfully developed in the form of mouth dissolving tablets with improved 
dissolution characteristic by forming solid dispersion with PEG 6000, which offers a 
suitable and practical approach in serving desired objective of faster disintegration 
and dissolution characteristics with increase bioavailability. Immediate release tablets 
of repaglinide were prepared by using natural superintegrants like microcrystalline 
cellulose, croscarmellose sodium, crospovidone, sodium starch glycolate and their 
combination as superdisintegrants. 
 Superdisintegrants work as an auxiliary or as a facilitator of the flowability 
and compressibility of the mixture and contribute to the immediate release of the 
tablet, due to its high solubility in water. 
 For the repaglinide formulation, batch No. 2 was chosen as it has 
disintegration time around 5-35 seconds and hardness3.5 Kg/Cm2. IR spectra of drug 
with other excipients has not shown any interaction and also selected formulation was 
stable after stability studies. 
CONCLUSION 
The solubility and dissolution rate of repaglinide can be enhanced by 
formulating SDs of repaglinide with PEG 6000.The solubilization effect of PEG 
6000, reduction of particle aggregation of the drug, formation of microcrystalline or 
amorphous drug, increased wetability and dispersibility, and alteration of the surface 
properties of the drug particles might be responsible for the enhanced solubility and 
dissolution rate of repaglinide from its SD and to some extent in PMs. No 
endothermic peak of repaglinide was present in of SDs with PEG 6000 suggesting the 
absence of crystalline repaglinide. From FTIR spectroscopy, it was concluded that 
there was no well defined chemical interaction between repaglinide and PEG 6000 in 
SDs and in PMs, as no important new peaks could be observed. 
The identical composition of Superdisintegrants showed that a substantial 
shorter time require for disintegration can be obtained and immediate release tablet 
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were prepared. The repaglinide immediate release tablet (F2) showed 78.72% drug 
release within first 5 min. and 99.50% drug release with in 30 min.  
 The results showed that the formulation satisfied the objective of fast 
disintegration, dissolution, % friability, hardness, wetting time, water absorption ratio, 
ease of administration and safety. 
 Success of the present study recommends a detailed investigation in to in-vivo 
studies for its effective use in clinical practice. 
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